Drug-Diagnostic Sponsors Must Educate Sites to Avoid Bias That Can Kill Approval

Drug Industry Daily
Sponsors of new drugs seeking approval with a companion in vitro diagnostic (IVD) need to work with trial sites to ensure they are not prescreening patients by local test methods — a process that can prove fatal for regulatory approval, an expert says.

To View This Article:


Subscribe To Drug Industry Daily